Aspirin, low molecular weight heparin, or both in preventing pregnancy complications in women with recurrent pregnancy loss and factor V Leiden mutation

dc.authoridBertan Akar / 0000-0003-0494-6867
dc.authorscopusidBertan Akar / 56439873300
dc.authorwosidBertan Akar / CCD-2869-2022
dc.date.accessioned2020-08-30T20:06:32Z
dc.date.available2020-08-30T20:06:32Z
dc.date.issued2020
dc.departmentİstinye Üniversitesi, Sağlık Bilimleri Fakültesi, Ebelik Bölümüen_US
dc.description.abstractObjective: The aim of this study was to compare the effects of low molecular weight heparin (LMWH), LMWH plus low dose aspirin, or low dose aspirin only on pregnancy outcomes in recurrent pregnancy loss (RPL) patients with factor V Leiden mutation (FVLM). Materials and methods: A total of 2764 RPL patients were evaluated in for the etiology of RPL. Mutations in factor V Leiden homozygous and heterozygous were determined. Subsequently, 196 of these patients were diagnosed with FVLM and included in the study; of these 174 completed the study. At the sixth week of gestation of subsequent pregnancy participants were randomly distributed into three groups. Group A (n?=?61) was composed of patients with an oral dose of 100?mg aspirin daily, Group B (n?=?59) consisted of patients using 40?mg enoxaparin and 100?mg orally aspirin daily, and Group C (n?=?54) included patients using 40?mg enoxaparin daily during pregnancy. Results: Among the 174 patients who completed the study, the live birth and miscarriage rates were similar for the three groups (p?=?.843 and p?=?.694, respectively). There was no significant difference among the groups in rates of eclampsia, placental abruption, intrauterine fetal growth restriction and gestational diabetes mellitus. The number of preeclamptic patients was significantly higher in Group A than Groups B and C. The levels of preterm birth was significantly higher in Group A than Groups B and C. Conclusion: Using low dose aspirin, LMWH plus aspirin, or LMWH alone yielded comparable live birth rates in RPL patients with FVLM. However, LMWH decreased the risk of preeclampsia in this group of patients. LMWH might therefore have a preventive role regarding preeclampsia.en_US
dc.identifier.citationKaradag, C., Akar, B., Gonenc, G., Aslancan, R., Yilmaz, N., & Caliskan, E. (2020). Aspirin, low molecular weight heparin, or both in preventing pregnancy complications in women with recurrent pregnancy loss and factor V Leiden mutation. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 33(11), 1934–1939. https://doi.org/10.1080/14767058.2019.1671348en_US
dc.identifier.doi10.1080/14767058.2019.1671348en_US
dc.identifier.endpage1939en_US
dc.identifier.issn1476-7058en_US
dc.identifier.issn1476-4954en_US
dc.identifier.issue11en_US
dc.identifier.pmid31550962en_US
dc.identifier.scopus2-s2.0-85074050727en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1934en_US
dc.identifier.urihttps://doi.org/10.1080/14767058.2019.1671348
dc.identifier.urihttps://hdl.handle.net/20.500.12713/551
dc.identifier.volume33en_US
dc.identifier.wosWOS:000488409300001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorAkar, Bertanen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal of Maternal-Fetal & Neonatal Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAspirinen_US
dc.subjectFactor V Leiden Mutationen_US
dc.subjectLive Birthen_US
dc.subjectLow Molecular Weight Heparinen_US
dc.subjectRecurrent Pregnancy Lossen_US
dc.titleAspirin, low molecular weight heparin, or both in preventing pregnancy complications in women with recurrent pregnancy loss and factor V Leiden mutationen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
33-.pdf
Boyut:
1.98 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text